CLEO: a multidimensional tool to assess clinical, economic and organisational impacts of pharmacists' interventions.
documentation
hospital
pharmacy service
professional competence
quality of health care
safety
Journal
European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
06
12
2020
revised:
05
03
2021
accepted:
22
03
2021
pubmed:
23
4
2021
medline:
2
4
2022
entrez:
22
4
2021
Statut:
ppublish
Résumé
Clinical pharmacists' interventions (PIs) are an important element in ensuring good pharmaceutical care. We aimed to develop and validate a comprehensive multidimensional tool for assessing the potential impact of PIs for daily practice of medication review. Experts of the French Society of Clinical Pharmacy (SFPC) developed the CLinical, Economic and Organisational (CLEO) tool, consisting of three independent dimensions concerning clinical, economic and organisational impact. They were asked to analyse 30 scenarios of PIs, and re-rated 10 PIs with a washout of 1 month (internal validation). Then, seven external experts not involved in the development of the tool rated 60 scenarios collected when using the CLEO in daily practice. Inter- and intra-rater reliabilities were determined by calculation of the intra-class correlation (ICC For internal reliability, the inter-rater reliability for the CLEO tool was good for clinical dimensions (ICC CLEO is a comprehensive tool assessing clinical, economic and organisational impacts of PIs which has been developed, validated and was reliable and feasible for use in routine clinical practice.
Identifiants
pubmed: 33883205
pii: ejhpharm-2020-002642
doi: 10.1136/ejhpharm-2020-002642
pmc: PMC8239266
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-200Commentaires et corrections
Type : CommentIn
Informations de copyright
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Pharm World Sci. 2006 Aug;28(4):222-32
pubmed: 17066238
Clin Ther. 1993 Nov-Dec;15(6):1121-32; discussion 1120
pubmed: 8111809
BMJ Open. 2020 Nov 27;10(11):e041563
pubmed: 33247028
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Pharmacotherapy. 2000 Oct;20(10 Pt 2):243S-252S
pubmed: 11034050
Am J Health Syst Pharm. 1997 Jul 15;54(14):1596-603
pubmed: 9248602
Drug Saf. 2016 Feb;39(2):131-46
pubmed: 26650064
Am J Hosp Pharm. 1990 Mar;47(3):533-43
pubmed: 2316538
BMC Health Serv Res. 2020 Feb 12;20(1):113
pubmed: 32050957
Am J Health Syst Pharm. 2006 Nov 15;63(22):2235-9
pubmed: 17090744
Science. 1978 May 26;200(4344):856-64
pubmed: 417400
Can J Hosp Pharm. 1990 Aug;43(4):167-71, 195
pubmed: 10105985
Int J Clin Pharm. 2019 Feb;41(1):56-64
pubmed: 30478493
Pharm World Sci. 2006 Aug;28(4):181-8
pubmed: 17066245
Ann Pharmacother. 1992 Dec;26(12):1580-4
pubmed: 1482816
Stat Med. 1998 Jan 15;17(1):101-10
pubmed: 9463853
Drug Intell Clin Pharm. 1988 Mar;22(3):252-9
pubmed: 3366065
J Clin Pharm Ther. 2015 Feb;40(1):32-40
pubmed: 25303720
Qual Health Care. 1992 Mar;1(1):5-9
pubmed: 10136831
J Clin Pharm Ther. 2012 Aug;37(4):459-63
pubmed: 22211951
Am J Health Syst Pharm. 1999 Dec 1;56(23):2444-50
pubmed: 10595804
Am J Hosp Pharm. 1992 May;49(5):1130-2
pubmed: 1595740
Medicine (Baltimore). 2018 Mar;97(9):e9865
pubmed: 29489684